Follicular lymphoma (FL) is a slow-growing, or “indolent,” type of non-Hodgkin lymphoma (NHL) that develops from B lymphocytes, a form of white blood cell. Because it progresses slowly, many individuals may not require immediate treatment after diagnosis. The disease usually begins in the lymph nodes but may also involve the bone marrow, spleen, and other organs as it advances. Although generally not curable with current therapies, Follicular Lymphoma is highly treatable, and many patients live for years or decades with effective disease management. This article will review what Follicular Lymphoma is, its causes and risk factors, how it develops, its symptoms, diagnostic process, treatment options, and long-term outlook.

Follicular Lymphoma is a subtype of non-Hodgkin lymphoma characterized by the abnormal growth of B lymphocytes. The term “follicular” refers to the clustered pattern of malignant cells that resemble normal lymphoid follicles when viewed under a microscope. FL is the second most common form of NHL, representing about 20–30% of cases. It occurs most often in adults over 60 years of age, though younger adults can also be affected. While considered incurable, it is often managed as a chronic illness with cycles of remission and relapse.

The exact cause of Follicular Lymphoma is not fully understood. Research shows that a combination of genetic, environmental, and immune-related factors may play a role. The disease often develops after certain mutations accumulate in B cells, but why these changes occur is not completely clear. Scientists believe both inherited predispositions and outside exposures may contribute to its development.

• Genetic changes: The most common is the t(14;18) chromosomal translocation, leading to overexpression of the BCL2 protein, which prevents normal cell death (apoptosis).
• Age and gender: The average age at diagnosis is about 60 years, and FL is slightly more common in women than men.
• Immune function: People with weakened immune systems (such as those with HIV/AIDS, organ transplants, or autoimmune diseases) are at higher risk.
• Environmental exposures: Long-term exposure to pesticides, herbicides, benzene, or radiation may increase risk, though evidence is limited.
• Family history: Having a first-degree relative with non-Hodgkin lymphoma raises the risk of FL.

It is important to note that Follicular Lymphoma is not infectious and cannot be spread from person to person.

Follicular Lymphoma begins when B lymphocytes acquire genetic mutations during normal development. These mutations allow the cells to:

• Avoid programmed cell death (apoptosis)
• Multiply uncontrollably
• Accumulate in lymph nodes and sometimes in other tissues or organs

The hallmark genetic abnormality is the BCL2 gene translocation, which makes malignant cells survive far longer than normal. Over time, these cells form tumors that may spread to distant sites. The exact cause of these mutations is unknown, but genetic predisposition combined with environmental influences likely plays a role.

Follicular Lymphoma is the second most common type of non-Hodgkin lymphoma. It accounts for about 20–30% of all NHL cases worldwide. The disease primarily affects older adults, with the median age at diagnosis being around 60. Cases in younger patients are uncommon but do occur. FL occurs slightly more often in women than men, and incidence is higher in North America and Europe compared to Asia.

Follicular Lymphoma often develops silently, meaning many people have no symptoms at first. It is sometimes discovered by chance during imaging or testing for another health issue. When signs do appear, they can differ widely depending on how far the disease has spread. Some people may notice only enlarged lymph nodes, while others may experience more systemic symptoms.

• Painless swollen lymph nodes: Most common, typically in the neck, armpits, or groin; may fluctuate in size.
• Systemic “B” symptoms: Less common early but may include fevers, drenching night sweats, and unintentional weight loss (>10% over six months).
• Fatigue: Persistent tiredness that affects daily activities, sometimes linked to anemia.
• Abdominal fullness or discomfort: Caused by an enlarged spleen or abdominal lymph nodes.
• Frequent infections or easy bruising: Due to impaired bone marrow function reducing healthy blood cell production.
• Skin lesions (rare): Nodules or rashes caused by lymphoma infiltration.

If bone marrow is involved, symptoms may include anemia (fatigue, shortness of breath) or thrombocytopenia (bruising, bleeding problems).

Diagnosis of Follicular Lymphoma is not based on a single test but instead requires several steps. Doctors typically combine a physical exam with blood tests, imaging scans, and tissue biopsy to confirm the disease. Each piece of information helps identify the type of lymphoma and how far it has spread. This careful approach ensures an accurate diagnosis and guides the most appropriate treatment plan.

• Physical exam: To detect enlarged lymph nodes, spleen, or liver.
• Blood tests: Complete blood count, LDH (marker of aggressive disease), and beta-2 microglobulin (indicator of tumor burden).
• Imaging studies: PET and CT scans to determine location and spread.
• Lymph node biopsy: The gold standard; pathology confirms abnormal follicles with markers such as CD10, CD20, BCL2, and BCL6.
• Bone marrow biopsy: To assess marrow involvement.
• Flow cytometry and genetic testing: Identifies clonal B cells and common translocations like t(14;18).
• Staging (Ann Arbor System): From Stage I (localized) to Stage IV (widespread disease including bone marrow/organ involvement).
• Biomarker testing and PCR: To detect specific genetic mutations with high sensitivity.

Differential diagnosis for Follicular Lymphoma

Because several conditions mimic Follicular Lymphoma, doctors must distinguish it from other lymphoid disorders, including:

• Reactive lymphoid hyperplasia
• Marginal zone lymphoma
• Mantle cell lymphoma
• Diffuse large B-cell lymphoma (especially if transformation occurs)

Accurate diagnosis requires biopsy and molecular testing.

Treatment for Follicular Lymphoma is highly individualized and depends on factors such as disease stage, symptoms, tumor burden, and overall health. Some patients may need treatment right away, while others can be safely monitored for months or even years. Doctors carefully weigh risks and benefits before recommending therapy, with the goal of controlling disease while preserving quality of life.

• Watchful waiting: Patients with asymptomatic, early-stage disease may undergo active surveillance with regular exams and scans.
• Radiation therapy: Used in early-stage disease, sometimes achieving long-term remission.
• Chemotherapy: Common regimens include bendamustine plus rituximab (BR) or R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone).
• Immunotherapy: Rituximab, a monoclonal antibody targeting CD20 on B cells, is widely used alone or with chemotherapy. Maintenance therapy may prolong remission.
• Targeted therapies: Agents such as PI3K inhibitors (copanlisib, idelalisib) and EZH2 inhibitors (tazemetostat) are options for relapsed or refractory disease.
• Stem cell transplantation: Autologous transplants may benefit relapsed or transformed FL. Allogeneic transplants are rare due to higher risks.
• CAR T-cell therapy: Axicabtagene ciloleucel (Yescarta) is FDA-approved for relapsed/refractory FL after multiple prior treatments.
• Clinical trials: Offer access to innovative therapies and combinations.

Complications may arise from both the disease and its treatments:

• Transformation into diffuse large B-cell lymphoma (more aggressive and life-threatening)
• Increased risk of infections (due to immune suppression or marrow involvement)
• Secondary cancers from chemotherapy or radiation
• Organ dysfunction from disease spread

Although considered incurable, Follicular Lymphoma often follows a chronic course. Many patients live for years, with survival measured in decades for some. The prognosis depends on disease stage, patient age, and whether transformation occurs. Advances in immunotherapy and targeted drugs have significantly improved outcomes.

There are no proven methods to prevent Follicular Lymphoma. General recommendations include:

• Minimizing unnecessary exposure to harmful chemicals or radiation
• Managing immune health through treatment of chronic infections and conditions
• Regular medical follow-up for those with a family history of lymphoma

Managing Follicular Lymphoma often feels like navigating a chronic illness. Patients may cycle between remission and relapse, which can be emotionally and physically challenging. Practical strategies include:

• Keeping consistent follow-up appointments
• Discussing lifestyle, treatment goals, and quality of life with healthcare providers
• Seeking counseling or support groups to cope with uncertainty
• Maintaining a balanced lifestyle with rest, exercise, and nutrition

Follicular Lymphoma is a common type of non-Hodgkin lymphoma that grows slowly and can often be managed for many years. While it is rarely curable, advances in targeted therapy, immunotherapy, and personalized medicine have greatly improved patient outcomes. Early diagnosis, careful monitoring, and individualized treatment planning are key to managing this disease. With ongoing research, the outlook for patients with Follicular Lymphoma continues to improve, offering new hope for long-term disease control and quality of life.

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition. International Agency for Research on Cancer; 2017.
2. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of transformation in Follicular Lymphoma in the immunochemotherapy era. J Clin Oncol. 2019;37(16):1446–1454.
3. Leonard JP, Davies A. Treatment advances in Follicular Lymphoma. J Clin Oncol. 2020;38(29):3307–3315.
4. Freedman A. Follicular Lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2018;93(2):296–305.